Publications by authors named "Gatmiri M"
Article Synopsis
- The study evaluates the effectiveness of three eGFR equations (Cockcroft-Gault, MDRD, and CKD-EPI) in measuring kidney function shortly after transplantation using a specific clearance method for comparison.
- Results showed that the Cockcroft-Gault method using total body weight had the best overall agreement with measured kidney function, especially for dosing certain drugs.
- The conclusion suggests using the Cockcroft-Gault formula for adjusting drug doses and either MDRD or CKD-EPI for staging kidney function, while acknowledging that these formulas often underestimate kidney function in early transplant patients.
Background: There is no treatment of choice for the management of acute antibody-mediated rejection (ABMR) in kidney transplant recipients. Plasmapheresis ± intravenous immunoglobulin (IVIg) ± rituximab has been used in different regimens with contradictory results.
Objective: To compare three regimens of acute ABMR management including plasmapheresis + IVIg ± rituximab in two different rituximab regimens.
Objective: Delayed graft function (DGF) is an early complication after kidney transplantation with negative impact on allograft outcomes. This study assessed the effect of delayed initiation of tacrolimus as a nephrotoxic drug, on DGF occurrence and allograft function.
Methods: This randomized, open-label clinical trial was conducted on kidney transplant recipients with the age of at least 14 years who underwent the first kidney transplantation from deceased or living donor.
Objectives: Compared to the general population, chronic kidney disease patients are more vulnerable to gastrointestinal haemorrhage and its morbidity and mortality. Due to the fear of gastrointestinal bleeding consequences in these patients on the one hand, and the perception of general safety of acid suppressive medications on the other hand, inappropriate stress ulcer prophylaxis (SUP) seems to be encountered in nephrology wards. The objectives of this study were to evaluate appropriateness of acid suppression therapy in kidney disease patients and to assess the role of clinical pharmacists to decrease inappropriate SUP prescribing and related costs for these patients.
View Article and Find Full Text PDFBackground: Compared with the general population, hemodialysis patients suffer from worse health-related quality of life (HRQoL). Poor HRQoL results in the higher risk of hospitalization and mortality.
Objective: This study was designed to assess the impact of pharmaceutical care on HRQoL of hemodialysis patients.